PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2144080
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2144080
Hemato Oncology Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2026 - 2032)
The global hemato oncology testing market stood at USD 4.1 billion in 2025 and is projected to reach USD 11.4 billion by 2032, expanding at a CAGR of 15.7% between 2026 and 2032. Growth is being driven by the rising clinical burden of hematological malignancies and a broader shift in diagnostic practice, moving from traditional morphology-based assessment toward integrated molecular, immunophenotypic, and cytogenetic profiling.
The scale of the underlying disease burden helps explain the pace of that shift. Research published in the Chinese Medical Journal recorded 1,311,104 new cases and 700,205 deaths from hematological malignancies worldwide in 2022, and the same study projects new cases to climb 69.6% by 2050. That trajectory is pushing hospitals and reference laboratories to build recurrent testing capacity rather than treat diagnosis as a one-time event.
A steady run of clinical trials for blood cancers, combined with growing awareness of advanced diagnostic options and more favorable reimbursement in several markets, is reinforcing this demand. Progress in understanding the molecular pathogenesis of diseases such as acute myeloid leukemia has also opened the door to more precise, biomarker-driven care.
Key Insights
By offering, services command the larger share of the market, at 70% in 2025, underpinned by rising leukemia, lymphoma, and multiple myeloma caseloads that require specialized laboratory expertise. Assay kits and reagents, on the other hand, are set to outpace services with a CAGR near 15.9%, as companion diagnostics and decentralized molecular testing gain ground.
By cancer type, lymphoma leads with 60% of the market in 2025 and the fastest CAGR, at roughly 16.0%, reflecting how many testing modalities, including immunohistochemistry, flow cytometry, cytogenetics, FISH, and molecular assays, a single lymphoma diagnosis can require.
Polymerase chain reaction holds the largest technology share, at 45% in 2025, thanks to its accuracy, speed, and lower cost relative to sequencing. Next-generation sequencing is climbing fastest, as sequencing costs fall and comprehensive genomic profiling becomes standard practice.
Hospitals account for 60% of end-user demand in 2025, given their diagnostic infrastructure and specialist staff. Academic and research institutes are growing quickest, at a CAGR of about 16.1%, as they validate new assays and run biomarker-driven trials.
North America leads the global market with a 40% share in 2025, supported by established reimbursement pathways for molecular pathology, a dense network of reference laboratories, and FDA-cleared assays such as clonoSEQ that have set a clinical precedent for sequencing-based monitoring.
The American Cancer Society projects 67,790 new leukemia cases and 23,910 leukemia deaths in the U.S. in 2026, alongside 79,320 new non-Hodgkin lymphoma cases. The National Cancer Institute's SEER program separately estimates 36,000 new multiple myeloma cases in the U.S. that year, with a five-year relative survival rate of 63.7% that extends the window in which patients need ongoing monitoring.
Asia-Pacific is the fastest-growing region, with a CAGR near 16.6%, as countries expand genomic and molecular diagnostic infrastructure. Japan approved its first comprehensive genomic profiling assay for blood cancers, HemeSight, in September 2024, with national health insurance reimbursement following in March 2025.
China remains the region's largest market on the strength of its patient population and expanding cancer center network. India is its fastest-growing, with the Indian Council of Medical Research projecting a 12.8% rise in total cancer incidence by 2025 versus 2020, as private diagnostic chains extend molecular testing beyond major cities.
Diagnostic classification is moving from morphology to genomics. The WHO's 5th edition classification of haematolymphoid tumours now incorporates molecular genetic abnormalities as diagnostic criteria for several malignancies, including acute myeloid leukemia, and the EU's SANGUINE project notes that blood cancers make up roughly 10% of the 2.7 million new cancer cases diagnosed annually across the bloc.
Measurable residual disease monitoring is emerging as a major growth avenue, turning diagnosis into an ongoing process across leukemia, lymphoma, and myeloma treatment. The World Health Organization notes that only 26% of low-income countries have generally available public pathology services, pointing to substantial room for laboratory network expansion. Reimbursement fragmentation and a shortage of hematopathologists, molecular pathologists, and bioinformatics specialists remain key constraints.
Recent product activity underscores the pace of innovation. Sysmex introduced its XR-Series hematology platform, including the XR-10 Automated Hematology Module with 3D scattergram technology, in May 2026. Invivoscribe launched its LeukoStrat KMT2A + MRD digital PCR assay in February 2026. Bio-Rad expanded its digital PCR footprint through its July 2025 acquisition of Stilla Technologies.
The competitive landscape remains fragmented across instrument makers, assay developers, sequencing providers, and clinical laboratory networks. F. Hoffmann-La Roche, Abbott Laboratories, Thermo Fisher Scientific, QIAGEN, Illumina, and Bio-Rad Laboratories hold strong positions in instruments, kits, and sequencing platforms. NeoGenomics widened its laboratory footprint in the Northeast U.S. through its April 2025 acquisition of Pathline, LLC, a move that also secured New York State testing approvals the company had previously lacked in the region.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market Size Breakdown, by Offering
- 1.4.2. Market Size Breakdown, by Cancer Type
- 1.4.3. Market Size Breakdown, by Technology
- 1.4.4. Market Size Breakdown, by End User
- 1.4.5. Market Size Breakdown, by Region
- 1.4.6. Market Size Breakdown, by Country
- 1.5. Market Data Reporting Unit
- 1.5.1. Revenue
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence Database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Industry Background
- 5.2. Market Dynamics
- 5.2.1. Trends
- 5.2.2. Drivers
- 5.2.3. Restraints/Challenges
- 5.2.4. Emerging Economies and Key Opportunities
- 5.2.5. Impact Analysis of Drivers/Restraints
- 5.3. Sociopolitical Impact
- 5.4. Porter's Five Forces Analysis
- 5.4.1. Bargaining Power of Buyers
- 5.4.2. Bargaining Power of Suppliers
- 5.4.3. Threat of New Entrants
- 5.4.4. Intensity of Rivalry
- 5.4.5. Threat of Substitutes
- 5.5. Lifecycle Analysis
- 5.6. Innovation and Technology Trends
- 5.7. Economic and Regulatory Impact
- 5.8. Market Entry Strategies
Chapter 6. Competitive Landscape
- 6.1. List of Market Players and their Offerings
- 6.2. Market Share of Key Players (2025)
- 6.2.1. Global
- 6.2.2. North America
- 6.2.3. Europe
- 6.2.4. Asia-Pacific
- 6.2.5. Latin America
- 6.2.6. Middle East and Africa
- 6.3. Competitive Benchmarking of Key Players
- 6.4. Product Benchmarking of Key Players
- 6.5. Recent Strategic Developments by Key Players
- 6.6. Company Leadership Matrix
Chapter 7. Global Market
- 7.1. Overview
- 7.2. Market Revenue, by Offering (2021-2032)
- 7.3. Market Revenue, by Cancer Type (2021-2032)
- 7.4. Market Revenue, by Technology (2021-2032)
- 7.5. Market Revenue, by End User (2021-2032)
- 7.6. Market Revenue, by Region (2021-2032)
Chapter 8. North America Market
- 8.1. Overview
- 8.2. Market Revenue, by Offering (2021-2032)
- 8.3. Market Revenue, by Cancer Type (2021-2032)
- 8.4. Market Revenue, by Technology (2021-2032)
- 8.5. Market Revenue, by End User (2021-2032)
- 8.6. Market Revenue, by Country (2021-2032)
Chapter 9. Europe Market
- 9.1. Overview
- 9.2. Market Revenue, by Offering (2021-2032)
- 9.3. Market Revenue, by Cancer Type (2021-2032)
- 9.4. Market Revenue, by Technology (2021-2032)
- 9.5. Market Revenue, by End User (2021-2032)
- 9.6. Market Revenue, by Country (2021-2032)
Chapter 10. Asia-Pacific Market
- 10.1. Overview
- 10.2. Market Revenue, by Offering (2021-2032)
- 10.3. Market Revenue, by Cancer Type (2021-2032)
- 10.4. Market Revenue, by Technology (2021-2032)
- 10.5. Market Revenue, by End User (2021-2032)
- 10.6. Market Revenue, by Country (2021-2032)
Chapter 11. Latin America Market
- 11.1. Overview
- 11.2. Market Revenue, by Offering (2021-2032)
- 11.3. Market Revenue, by Cancer Type (2021-2032)
- 11.4. Market Revenue, by Technology (2021-2032)
- 11.5. Market Revenue, by End User (2021-2032)
- 11.6. Market Revenue, by Country (2021-2032)
Chapter 12. Middle East and Africa Market
- 12.1. Overview
- 12.2. Market Revenue, by Offering (2021-2032)
- 12.3. Market Revenue, by Cancer Type (2021-2032)
- 12.4. Market Revenue, by Technology (2021-2032)
- 12.5. Market Revenue, by End User (2021-2032)
- 12.6. Market Revenue, by Country (2021-2032)
Chapter 13. U.S. Market
- 13.1. Overview
- 13.2. Economic Indicators
- 13.3. Demographics and Population Insights
- 13.4. Growth Drivers
- 13.5. Challenges and Barriers
- 13.6. Competitive Strategies
- 13.7. Emerging Players
- 13.8. Market Size and Forecast
- 13.8.1. Market Revenue, by Offering (2021-2032)
- 13.8.2. Market Revenue, by Cancer Type (2021-2032)
- 13.8.3. Market Revenue, by Technology (2021-2032)
- 13.8.4. Market Revenue, by End User (2021-2032)
Chapter 14. Canada Market
- 14.1. Overview
- 14.2. Economic Indicators
- 14.3. Demographics and Population Insights
- 14.4. Growth Drivers
- 14.5. Challenges and Barriers
- 14.6. Competitive Strategies
- 14.7. Emerging Players
- 14.8. Market Size and Forecast
- 14.8.1. Market Revenue, by Offering (2021-2032)
- 14.8.2. Market Revenue, by Cancer Type (2021-2032)
- 14.8.3. Market Revenue, by Technology (2021-2032)
- 14.8.4. Market Revenue, by End User (2021-2032)
Chapter 15. Germany Market
- 15.1. Overview
- 15.2. Economic Indicators
- 15.3. Demographics and Population Insights
- 15.4. Growth Drivers
- 15.5. Challenges and Barriers
- 15.6. Competitive Strategies
- 15.7. Emerging Players
- 15.8. Market Size and Forecast
- 15.8.1. Market Revenue, by Offering (2021-2032)
- 15.8.2. Market Revenue, by Cancer Type (2021-2032)
- 15.8.3. Market Revenue, by Technology (2021-2032)
- 15.8.4. Market Revenue, by End User (2021-2032)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Economic Indicators
- 16.3. Demographics and Population Insights
- 16.4. Growth Drivers
- 16.5. Challenges and Barriers
- 16.6. Competitive Strategies
- 16.7. Emerging Players
- 16.8. Market Size and Forecast
- 16.8.1. Market Revenue, by Offering (2021-2032)
- 16.8.2. Market Revenue, by Cancer Type (2021-2032)
- 16.8.3. Market Revenue, by Technology (2021-2032)
- 16.8.4. Market Revenue, by End User (2021-2032)
Chapter 17. France Market
- 17.1. Overview
- 17.2. Economic Indicators
- 17.3. Demographics and Population Insights
- 17.4. Growth Drivers
- 17.5. Challenges and Barriers
- 17.6. Competitive Strategies
- 17.7. Emerging Players
- 17.8. Market Size and Forecast
- 17.8.1. Market Revenue, by Offering (2021-2032)
- 17.8.2. Market Revenue, by Cancer Type (2021-2032)
- 17.8.3. Market Revenue, by Technology (2021-2032)
- 17.8.4. Market Revenue, by End User (2021-2032)
Chapter 18. Italy Market
- 18.1. Overview
- 18.2. Economic Indicators
- 18.3. Demographics and Population Insights
- 18.4. Growth Drivers
- 18.5. Challenges and Barriers
- 18.6. Competitive Strategies
- 18.7. Emerging Players
- 18.8. Market Size and Forecast
- 18.8.1. Market Revenue, by Offering (2021-2032)
- 18.8.2. Market Revenue, by Cancer Type (2021-2032)
- 18.8.3. Market Revenue, by Technology (2021-2032)
- 18.8.4. Market Revenue, by End User (2021-2032)
Chapter 19. Spain Market
- 19.1. Overview
- 19.2. Economic Indicators
- 19.3. Demographics and Population Insights
- 19.4. Growth Drivers
- 19.5. Challenges and Barriers
- 19.6. Competitive Strategies
- 19.7. Emerging Players
- 19.8. Market Size and Forecast
- 19.8.1. Market Revenue, by Offering (2021-2032)
- 19.8.2. Market Revenue, by Cancer Type (2021-2032)
- 19.8.3. Market Revenue, by Technology (2021-2032)
- 19.8.4. Market Revenue, by End User (2021-2032)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Economic Indicators
- 20.3. Demographics and Population Insights
- 20.4. Growth Drivers
- 20.5. Challenges and Barriers
- 20.6. Competitive Strategies
- 20.7. Emerging Players
- 20.8. Market Size and Forecast
- 20.8.1. Market Revenue, by Offering (2021-2032)
- 20.8.2. Market Revenue, by Cancer Type (2021-2032)
- 20.8.3. Market Revenue, by Technology (2021-2032)
- 20.8.4. Market Revenue, by End User (2021-2032)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Economic Indicators
- 21.3. Demographics and Population Insights
- 21.4. Growth Drivers
- 21.5. Challenges and Barriers
- 21.6. Competitive Strategies
- 21.7. Emerging Players
- 21.8. Market Size and Forecast
- 21.8.1. Market Revenue, by Offering (2021-2032)
- 21.8.2. Market Revenue, by Cancer Type (2021-2032)
- 21.8.3. Market Revenue, by Technology (2021-2032)
- 21.8.4. Market Revenue, by End User (2021-2032)
Chapter 22. Japan Market
- 22.1. Overview
- 22.2. Economic Indicators
- 22.3. Demographics and Population Insights
- 22.4. Growth Drivers
- 22.5. Challenges and Barriers
- 22.6. Competitive Strategies
- 22.7. Emerging Players
- 22.8. Market Size and Forecast
- 22.8.1. Market Revenue, by Offering (2021-2032)
- 22.8.2. Market Revenue, by Cancer Type (2021-2032)
- 22.8.3. Market Revenue, by Technology (2021-2032)
- 22.8.4. Market Revenue, by End User (2021-2032)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Economic Indicators
- 23.3. Demographics and Population Insights
- 23.4. Growth Drivers
- 23.5. Challenges and Barriers
- 23.6. Competitive Strategies
- 23.7. Emerging Players
- 23.8. Market Size and Forecast
- 23.8.1. Market Revenue, by Offering (2021-2032)
- 23.8.2. Market Revenue, by Cancer Type (2021-2032)
- 23.8.3. Market Revenue, by Technology (2021-2032)
- 23.8.4. Market Revenue, by End User (2021-2032)
Chapter 24. Australia Market
- 24.1. Overview
- 24.2. Economic Indicators
- 24.3. Demographics and Population Insights
- 24.4. Growth Drivers
- 24.5. Challenges and Barriers
- 24.6. Competitive Strategies
- 24.7. Emerging Players
- 24.8. Market Size and Forecast
- 24.8.1. Market Revenue, by Offering (2021-2032)
- 24.8.2. Market Revenue, by Cancer Type (2021-2032)
- 24.8.3. Market Revenue, by Technology (2021-2032)
- 24.8.4. Market Revenue, by End User (2021-2032)
Chapter 25. Brazil Market
- 25.1. Overview
- 25.2. Economic Indicators
- 25.3. Demographics and Population Insights
- 25.4. Growth Drivers
- 25.5. Challenges and Barriers
- 25.6. Competitive Strategies
- 25.7. Emerging Players
- 25.8. Market Size and Forecast
- 25.8.1. Market Revenue, by Offering (2021-2032)
- 25.8.2. Market Revenue, by Cancer Type (2021-2032)
- 25.8.3. Market Revenue, by Technology (2021-2032)
- 25.8.4. Market Revenue, by End User (2021-2032)
Chapter 26. Mexico Market
- 26.1. Overview
- 26.2. Economic Indicators
- 26.3. Demographics and Population Insights
- 26.4. Growth Drivers
- 26.5. Challenges and Barriers
- 26.6. Competitive Strategies
- 26.7. Emerging Players
- 26.8. Market Size and Forecast
- 26.8.1. Market Revenue, by Offering (2021-2032)
- 26.8.2. Market Revenue, by Cancer Type (2021-2032)
- 26.8.3. Market Revenue, by Technology (2021-2032)
- 26.8.4. Market Revenue, by End User (2021-2032)
Chapter 27. Saudi Arabia Market
- 27.1. Overview
- 27.2. Economic Indicators
- 27.3. Demographics and Population Insights
- 27.4. Growth Drivers
- 27.5. Challenges and Barriers
- 27.6. Competitive Strategies
- 27.7. Emerging Players
- 27.8. Market Size and Forecast
- 27.8.1. Market Revenue, by Offering (2021-2032)
- 27.8.2. Market Revenue, by Cancer Type (2021-2032)
- 27.8.3. Market Revenue, by Technology (2021-2032)
- 27.8.4. Market Revenue, by End User (2021-2032)
Chapter 28. South Africa Market
- 28.1. Overview
- 28.2. Economic Indicators
- 28.3. Demographics and Population Insights
- 28.4. Growth Drivers
- 28.5. Challenges and Barriers
- 28.6. Competitive Strategies
- 28.7. Emerging Players
- 28.8. Market Size and Forecast
- 28.8.1. Market Revenue, by Offering (2021-2032)
- 28.8.2. Market Revenue, by Cancer Type (2021-2032)
- 28.8.3. Market Revenue, by Technology (2021-2032)
- 28.8.4. Market Revenue, by End User (2021-2032)
Chapter 29. U.A.E. Market
- 29.1. Overview
- 29.2. Economic Indicators
- 29.3. Demographics and Population Insights
- 29.4. Growth Drivers
- 29.5. Challenges and Barriers
- 29.6. Competitive Strategies
- 29.7. Emerging Players
- 29.8. Market Size and Forecast
- 29.8.1. Market Revenue, by Offering (2021-2032)
- 29.8.2. Market Revenue, by Cancer Type (2021-2032)
- 29.8.3. Market Revenue, by Technology (2021-2032)
- 29.8.4. Market Revenue, by End User (2021-2032)
Chapter 30. Company Profiles
Chapter 31. Appendix
- 31.1. Sources and References
- 31.2. Related Reports
